CD177 and neoplasm: One of the strategies pursued to personalize disease management in oncological settings is called tumor targeting: utilizing the overexpression of cell surface receptors in tumors for the accumulation of high-affinity ligands equipped with suitable effectors, typically radionuclides, for imaging or therapy [65,66].